Analytical Data
-
基因名
Virus-Like Particles (VLPs) isotype control
-
简介
Fluorescent VLP with a GFP tag, self-assembles from viral envelope/capsid proteins, serving as a control for VLPs displaying membrane proteins. Formed in HEK293 cultures, these VLPs concentrate membrane proteins on the cell surface, producing high-concentration proteins ideal for immunization and antibody screening.
- Application
-
种属
Virus
-
表达系统
HEK293
-
标签
GFP
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Virus-Like Particles (VLPs) have emerged as a promising platform for vaccine development and immunotherapy due to their ability to mimic the structure of real viruses without containing viral genetic material. These particles can elicit strong immune responses, making them ideal candidates for antigen delivery. In research involving VLPs, isotype control recombinant proteins play a crucial role in validating experimental results, particularly in immunological assays. Isotype controls are antibodies of the same species and subclass as the test antibodies, which lack specific binding to the target antigen. In studies utilizing VLPs, these controls help ensure that observed immune responses are indeed due to the specific interactions with the VLPs rather than non-specific binding or background noise. The development of isotype control VLPs allows researchers to systematically assess the efficacy and specificity of the immune response elicited by VLP-based vaccines or therapies. As VLP technology advances, understanding the nuanced interactions between VLPs and the immune system becomes essential for optimizing their design and improving vaccine efficacy. This focus on isotype controls ultimately enhances the reliability and interpretability of findings in the burgeoning field of VLP research, paving the way for innovative applications in disease prevention and treatment.
